Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02698215 · ClinicalTrials.gov registry record · Phase 2
Combining Varenicline and Naltrexone for Smoking Cessation
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT02698215 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 165 participants.
The verdict
NCT02698215, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This study is a double-blind, randomized clinical trial using a two group medication design consisting of the combination of VAR (1 mg twice daily) + NTX (50 mg once daily) and VAR (1 mg twice daily) + PLA (matched to NTX), for smoking cessation in a sample of heavy drinking daily smokers who want to quit smoking and reduce drinking.
Interventions
- DRUG Varenicline
- DRUG Varenicline plus Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02698215
The ClinicalTrials.gov registry entry for NCT02698215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Varenicline is the first listed.
NCT02698215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02698215 about?
NCT02698215 is a clinical study titled "Combining Varenicline and Naltrexone for Smoking Cessation". This study is a double-blind, randomized clinical trial using a two group medication design consisting of the combination of VAR (1 mg twice daily) + NTX (50 mg once daily) and VAR (1 mg twice daily) + PLA (matched to NTX), for smoking cessation in a sample of heavy drinking daily smokers who want t...
What is the current status of trial NCT02698215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2016-05. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02698215?
The interventions under investigation include: Varenicline (DRUG), Varenicline plus Naltrexone (DRUG).
Who is sponsoring clinical trial NCT02698215?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.